Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNV1521 in Advanced Solid Tumors
NCT06220864Phase 1Recruiting
- Sponsor
- Synnovation Therapeutics
- Start
- Feb 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of SNV1521 in solid tumor (10 arms), sponsored by Synnovation Therapeutics. Primary endpoints: Safety of SNV1521 up to 13 months and Tolerability of SNV1521 at 28 days. Started Feb 2024; status: recruiting.
02
Drugs
SNV1521
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06220864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06220864.